Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Objective Evaluate open-label sarilumab monotherapy in patients with rheumatoid arthritis switching from adalimumab monotherapy in MONARCH (NCT02332590); assess long-term safety and efficacy in patients continuing sarilumab during open-label extension (OLE).Methods During the 48-week OLE, patients r...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerd R Burmester, Mark C Genovese, Vibeke Strand, Gregory St John, Andrea Rubbert-Roth, Howard Amital, Tatiana Raskina, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Susan Boklage
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/5/2/e001017.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items